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Abstract
Diffuse large B-cell lymphoma (DLBCL) is a heterogenous class of  aggressive 
lymphoma and is considered as the most common subtype of non-Hodgkin 
 lymphomas (NHL). Several genetic anomalies such as point mutations, numerical 
alterations, and, more rarely, translocations and gene amplifications play a role in 
the pathogenesis of this class of B-cell lymphoma and have been related to specific 
histological and immunophenotypic subtypes. On the other hand, the treatment 
protocol in DLBCL did not witness significant changes during the last two decades. 
The widespread adoption of rituximab as an important adjuvant to standard 
chemotherapy protocol in CD20+ cases was a notable exception, which provided 
significant improvement in disease-free survival and overall survival, with limited 
toxicity. However, no less than 20% of patients diagnosed with DLBCL exhibit 
relapse after the initial response to R-CHOP regimen, while more than 15% of the 
patients exhibit primary refractory disease. This is the reason why a review of all 
the morphological, clinical, and therapeutic particularities of DLBCL is required.
Keywords: diffuse large B-cell lymphoma, immunohistochemistry, lymphoma, 
molecular diagnostics, rituximab-CHOP
1. Introduction
Non-Hodgkin lymphomas (NHL) are the most common type of lymphoma, 
accounting for roughly 85% of this category of lymphoid neoplasia. NHL are most 
commonly classified as B-cell, T-cell, and natural killer (NK) cell lymphomas, 
according to their cell of origin. Diffuse large B-cell lymphoma (DLBCL) is a 
heterogenous class of aggressive lymphoma and is considered as the most common 
subtype of NHL. Several genetic anomalies such as point mutations, numerical 
alterations, and, more rarely, translocations and gene amplifications play a role in 
the pathogenesis of this class of B-cell lymphoma and have been related to specific 
histological and immunophenotypic subtypes [1].
2. Etiopathogeny of diffuse large B-cell lymphoma
2.1 Epidemiology
The incidence of diffuse large B-cell lymphoma (DLBCL) is increasing with 
age, from 0.3 cases/100,000/year in those between the ages of 35 and 39 years and 
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26.6/100,000/year for the 80- to 84-year-old age group [2, 3]. Mean age of diagnosis 
is 65 years for DLBCL and between 20 and 30 years of age for primary mediastinal 
subtype [4].
This type of lymphoma is more common in Caucasians than African and Asian 
populations, while the extranodal involvement is more frequent in European and 
the Far East population than the American patients. The sex ratio ranges from 1.5 to 
3.5/1 in favor of men [5].
2.2 Pathogeny
DLBCL originates in mature B cells in certain stages of differentiation. Various 
changes occur in the B cell toward its malignant transformation, which are 
induced by genetic mutations. During their ontogenesis, the B cells are passing in 
the secondary lymphoid tissues where the antigen-dependent activation occurs. 
The activation and amassment of B cells in the secondary lymphoid tissue lead 
to the creation of the germinal center, which is critically dependent on BCL-6. If 
certain genetic alterations occur during lymphocyte development, then the deter-
minatives of the neoplastic changes are settled. The type of lymphoma is deter-
mined by the stage of maturation of the B cell and by the type of anomalies that are 
interfering with their development and differentiation [6]. More specifically, the 
upregulation of B-cell lymphoma-2 (Bcl-2) protein expression and the inactivation 
of BCL6 which in turn blocks the apoptosis have both been observed in DLBCL.
Moreover, the elevation of the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFkB) and the upregulation of the avian myelocytomatosis virus 
oncogene cellular homolog (c-Myc) expression, leading to an increase in B cell 
proliferation, have also been cited [7]. The signal pathways for the B-cell receptor 
(BCR) and the activation of NFkB and downregulation of the B-cell lymphoma-6 
(Bcl-6) pathways have a special pathogenic significance in DLBCL [7].
3. Classification and standardization
3.1 Classification
DLBCL can originate from three types of cells and can be classified accordingly 
as germinal center DLBCL (GCB DLBCL), from the centroblasts of the germinal 
center; activated B-cell DLBCL (ABC-DLBCL), from the plasmablasts that are 
involved in the terminal differentiation of the B cells; and primary mediastinal 
large B-cell lymphoma (PMBCL), which derives from thymic B cells. This clas-
sification has a prognostic utility, as the activated B-cell subtype has an unfavorable 
evolution [8].
Apart from the cell-of-origin classification, several other classifications for non-
Hodgkin lymphomas have been suggested during the last half-century, each with its 
own advantages and drawbacks: Rappaport, Kiel, International Working Formulation 
(IWF), and the Revised European-American Lymphoma classification (REAL). The 
last classification that is currently in use has been offered by the World Health 
Organization (WHO) in 2001 and was last revised in 2016. According to the matu-
ration stage in which the B cell is in, and to the type of anomalies that occur during 
differentiation and maturation, DLBCL presents several variants and subtypes.
The World Health Organization classification of the lymphoid neoplasms has 
systemized DLBCL into several subtypes, each with its own morphological, clinical, 
and immunohistochemical particularities. The 2016 revision of the WHO clas-
sification brought several updates concerning diagnostic and prognostic factors 
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for DLBCL, such as the acknowledgment of the prognostic role of double-hit 
DLBCL-NOS, which involves the double expression of MYC and BCL2, or the newly 
introduced designation of DLBCL EBV+ (NOS) which is replacing the old term of 
“DLBCL EBV+ of the elderly” (Table 1) [9].
Chronic lymphocytic leukemia/small lymphocytic lymphoma
Monoclonal B-cell lymphocytosis
B-Cell prolymphocytic leukemia
Splenic marginal zone lymphoma
Hairy cell leukemia
Splenic B-cell lymphoma/leukemia, unclassifiable
 Splenic diffuse red pulp small B-cell lymphoma
 Hairy cell leukemia variant
Lymphoplasmacytic lymphoma
Waldenstrom macroglobulinemia
Monoclonal gammopathy of undetermined significance (MGUS), IgM
 m heavy-chain disease
 g heavy-chain disease
 a heavy-chain disease
Monoclonal gammopathy of undetermined significance (MGUS), IgG/A
Plasma cell myeloma
Solitary plasmacytoma of bone
Extraosseous plasmacytoma
Monoclonal immunoglobulin deposition diseases
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
Nodal marginal zone lymphoma
 Pediatric nodal marginal zone lymphoma
Follicular lymphoma
 In situ follicular neoplasia
 Duodenal-type follicular lymphoma
Pediatric-type follicular lymphoma
Large B-cell lymphoma with IRF4 rearrangement
Primary cutaneous follicle center lymphoma
Mantle cell lymphoma
 In situ mantle cell neoplasia
Diffuse large B-cell lymphoma (DLBCL), NOS
 Germinal center B-cell type
 Activated B-cell type
T-cell/histiocyte-rich large B-cell lymphoma
Primary DLBCL of the central nervous system (CNS)
Primary cutaneous DLBCL, leg type
EBV1 DLBCL, NOS
EBV1 mucocutaneous ulcer
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3.2 Variants of DLBCL and related pathologic entities
Over time, several variants and subtypes of DLBCL have been identified, 
according to their clinical features, localization, and morphology, which are all 
included in the recent REAL and WHO classifications. Extranodal DLBCL are 
relatively rare, accounting for 1–5% of NHL [10]. Less than 40% of DLBCL cases 
are originating in extranodal sites, especially in the gastrointestinal tract but also 
the mediastinum, bones, central nervous system (CNS), testes, and breast [11].
3.2.1 Primary mediastinal large B-cell lymphoma (PMBCL)
Roughly 10% of the total number of DLBCL is represented by PMBCL, a subtype 
which originates in medullary thymic B cells and affects young women, around the 
age of 30 and 40 years. They clinically appear as large mediastinal tumors some-
times involving the lungs and pericardium, which can lead to local compression 
with superior vena cava syndrome and airway obstruction. PMBCL is positive for 
pan-B markers, CD23 and CD30, and is negative to CD15 and sIg. BCL6, CD10, and 
interferon regulatory factor 4 (IRF4) can sometimes be positive [12]. Several chro-
mosomal abnormalities can be found, such as gains in chromosomal arm 9p and 2p 
corresponding to JAK2 and cREL loci [13, 14]. Because of the diagnosis confusions 
between PMBCL and DLBCL with secondary mediastinal involvement, the reports 
concerning the survival rates of the two pathologic entities have been similar [15].
More recently the improvements in diagnosis of PMBCL have allowed to observe 
a higher survival rate of this type of lymphoma compared to DLBCL [16]. Some 
variants of PMBCL, which own morphologic, immunophenotypical, and molecular 
resemblance with the nodular sclerosis subtype of Hodgkin lymphoma, are included 
in the category of B-cell lymphoma, unclassifiable, with features intermediate 
between DLBCL and classical Hodgkin lymphoma [9, 10, 17].
3.2.2 Primary DLBCL of the central nervous system (CNS)
Only a limited number of cases (2–3%) of cerebral neoplasms are lympho-
mas, the most frequent of which is DLBCL. Primary DLBCL of CNS can be both 
DLBCL associated with chronic inflammation
Lymphomatoid granulomatosis
Primary mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma





Burkitt-like lymphoma with 11q aberration
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements
High-grade B-cell lymphoma, NOS
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin 
lymphoma
Table 1. 
2016 WHO classification of mature B-cell neoplasms [9].
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germinal center and non-germinal center, while some genetic anomalies suggest the 
implication of the microenvironment as a pathogenic factor [18].
The clinical manifestations usually range from neurological deficits to psychi-
atric symptoms, but ocular involvement, seizures, and symptoms of increased 
intracranial pressure can also be found [18].
3.2.3 Primary testicular lymphomas (PTL)
PTL are usually DLBCL (>80%) but can also classified as follicular, plasmablas-
tic, Burkitt, mantle cell, or plasmablastic lymphomas in a minority of cases. Usually 
this type of lymphoma is diagnosed in stages 1–2, while in advanced stages, it can 
also affect the central nervous system, the liver, the skin, the Waldeyer ring, and the 
lungs [19]. PTL displays a modified expression of adhesion molecules that can be 
correlated with extranodal involvement. In most cases (60–96%) the cell of origin 
analysis indicates the activated B-cell (ABC) pattern. Several mutations have been 
observed, such as MYD88 mutations in 70% of cases, rearrangements of forkhead 
box protein P1 (FOXP1), programmed death-ligand 1 (PDL 1), and class II MHC 
transactivator (CIITA), as well as inactivation mutations of beta-2 microglobulin 
(B2M) gene [10].
3.2.4 Primary breast lymphoma
Primary breast lymphoma is a rare form of breast cancer, with cell of origin 
studies usually indicating an activated B-cell pattern. The cytogenetic analysis 
shows multiple chromosomal anomalies, such as trisomies 3 and 18 and transloca-
tions of chromosome 18 involving IGH/MALT1 [20].
3.2.5 Primary bone lymphoma (PBoL)
PBoL is a rare type of lymphoma that is confined to the bone tissue, prepon-
derantly affecting the middle-aged male patients. It should be differentiated from 
primary medullar lymphoma which, unlike PBoL, does not display cortical involve-
ment [21]. The germinal center subtype is more common, frequently displaying 
BCL2, BCL6, and MYC rearrangements [10].
4. Clinical, morphologic, and cytogenetic characteristics
4.1 Clinical aspects
DLBCL patients have a wide spectrum of clinical manifestations, a frequent 
nodal involvement, but also, in up to 40% of cases, extranodal symptoms (skin, 
digestive and central nervous system, etc.). All these clinical manifestations, 
together with the general signs and symptoms (such as fever, weight loss, sweat-
ing) usually indicate a more aggressive phenotype. On rare occasions, the diagnosis 
is incidentally established when the clinical examination detects enlarged lymph 
nodes with no other signs or symptoms. Medullary involvement is uncommon in the 
early phases of the disease, as it is only found in less than 30% of cases [22].
As for the paraclinical investigations, usual blood tests consist in complete blood 
count, lactate dehydrogenase and uric acid determination, serology, osteomedular 
biopsy, and cytologic exam of the cerebrospinal fluid. Computed tomography 
(CT) scan or, even better, positron emission tomography–computed tomography 
(PET-CT) is considered mandatory to assess the extension of the disease.
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PET-CT is of great diagnostic and prognostic importance, but it is also neces-
sary for the post-chemotherapy assessment, such that in case of negative scans at 
the end of chemotherapy regimen, the overall prognosis is favorable [23, 24]. The 
drawbacks of this technique consist of the possibility of false-positive results due 
to reversible thymic hyperplasia, infections, and sarcoidosis or as a consequence of 
hematopoietic growth factor therapy [23].
4.2 Morphologic and cytogenetic characteristics
The search for an exclusively cytologic classification of DLBCL is mostly aban-
doned, due to the wide observer-dependent variations in morphologic analysis and 
nosologic framing. The cytologic exam usually differentiates between centroblastic, 
immunoblastic, anaplastic, and T-cell/histiocyte-rich B-cell lymphoma.
The subtype of DLBCL is decided by the genetic anomalies that occur during 
B-cell differentiation and maturation process [6, 25].
Even though gene expression profiling has the best accuracy for the identifica-
tion of the cell of origin in DLBCL, its numerous drawbacks—such as the diverse 
cellular regulating pathways, some financial limitations, etc.—make its widespread 
clinical use still impractical. Consequently, several surface molecules have been 
evaluated for the differentiation between GCB and ABC DLBCL, which prove to be 
consistent with gene expression profiling.
The Hans algorithm has structured DLBCL in these two main subtypes, by 
analyzing three essential markers: multiple myeloma 1 protein (MUM1), CD10, 
and bcl-6 (Figure 1). The same classification can be achieved by using the ger-
minal center B cell-expressed transcript 1 (GCET1), CD10, BCL-6, MUM1, and 
FOXP1 biomarkers (the Tally and Choi algorithms) with a slightly better accuracy 
(Figure 2). All these algorithms are important, as the cell of origin classifica-
tion tends to display a prognostic role, due to the fact that DLBCL-GCB subtype 
usually has a favorable prognosis compared to non-GCB subtype. To further 
add to the complexity of this classification, GC and ABC DLBCL subtypes also 
express several particularities in cell marker expression, activation pathways, and 
outcomes [26].
However, the detection of other cell marker expression has become a fundamen-
tal component both in establishing an accurate prognosis and in the development of 
an optimal therapeutic algorithm.
Figure 1. 
Hans algorithm for DLBCL subtyping.
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5. Treatment of diffuse large B-cell lymphoma
The treatment protocol in DLBCL did not witness significant changes dur-
ing the last two decades. The widespread adoption of rituximab as an important 
adjuvant to standard chemotherapy protocol in CD20+ cases was a notable excep-
tion, which provided significant improvement in disease-free survival, overall 
survival, and complete remission rates, with limited toxicity. However, no less than 
20% of patients diagnosed with DLBCL exhibit relapse after the initial response 
to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and pred-
nisone) regimen, while more than 15% of the patients exhibit primary refractory 
disease [27]. All these factors required the search for alternative therapeutic 
regimens, such as R-CHOEP (rituximab, cyclophosphamide, doxorubicin, vin-
cristine, etoposide, and prednisone), R-miniCHOP (adjusted short-term R-CHOP 
therapy), R-ACVBP (adriamycin-cytoxan-vindesine-bleomycin-prednisone-
rituximab), etc., that are strictly codified by several therapeutic protocols, such as 
the 2015 ESMO guidelines [10].
The choice for any of these regimens should be adapted to the specific clinical 
status of each patient, as the exact therapy depends on a number of factors, such 
as the stage of the disease, age, and biological status. However, despite numerous 
attempts, no clear recommendation has been published thus far.
The association of radiation therapy to chemotherapy offered conflicting results. 
While some studies showed some benefits for the combined therapy, most of the 
authors did not find any real advantages, especially in the case of localized disease 
without bulky mass [28]. There were some suggestions of a combined therapeutic 
algorithm, involving four R-CHOP cycles followed by either local radiation therapy 
or two more cycles of R-CHOP, in the case of complete remission. Armitage et al. 
pleaded for mandatory radiation therapy after six cycles of R-CHOP in the case 
of bulky disease [29]. More recently MInT (MabThera International Trial) study 
recommended the same therapeutic algorithm for localized bulky disease [30].
In the case of localized disease, the therapeutic protocol varies with the specific 
organ involvement. For primary DLBCL of the testis, R-CHOP should be associated 
with radiotherapy and methotrexate or intrathecal cytarabine, due to the potential 
risk of CNS involvement. In case of documented CNS involvement before the onset 
of therapy, then high-dose intravenous and intrathecal methotrexate is advised. 
Conversely, cytarabine should be used instead of methotrexate for lymphoma-
tous meningitis [31]. R-CEOP can be advised for patients with an altered cardiac 
function.
In the case of advanced stage DLBCL, the therapeutic options varied greatly 
since the early 1980s. The third-generation regimens, ProMACE/CytaBOM 
Figure 2. 
Choi algorithm for DLBCL subtyping.
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(cyclophosphamide, doxorubicin, etoposid, Cytosar, bleomycin, vincristine, 
methotrexate, prednisone) and M-BACOD (methotrexate, bleomycin, doxorubi-
cin, cyclophosphamide, vincristine, and dexamethasone), showed no benefits for 
complete remission or disease-free survival when compared to CHOP. However, a 
lower toxicity for CHOP was observed [32].
The R-ACVBP regimen, consisting of rituximab, doxorubicin, cyclophospha-
mide, vindesine, bleomycin, and prednisone, for induction of remission, and 
consolidation with methotrexate, doxorubicin, and cyclophosphamide, was tested 
by the GELA (Groupe d’Etude des Lymphomes de l’Adulte) study on 379 patients. 
This regimen showed some advantages over the R-CHOP-21 but at the price of 
significantly higher toxicity [33].
Given these circumstances, there is a growing need for new therapeutic alterna-
tives, fitted for the morphologic, immunohistochemical, and genetic profile of each 
patient selected for individualized treatment protocol.
The role of immunophenotype variability for the therapeutic outcome has 
long been the cornerstone for DLBCL management strategy, largely because the 
treatment of lymphomas evolves toward new therapies (immunotherapy, targeted 
therapy), which is made possible by analyzing the biology and the signaling path-
ways of this disease [34, 35]. Furthermore, a growing number of biological agents 
are available, varying from interferon to rituximab or radiolabeled antibodies, but 
also the more recent acquisitions in targeted therapy, such as ibrutinib, acalabruti-
nib, and daratumumab [36–38].
6. Conclusions
Despite the numerous advances and better understanding of the clinical, immu-
nophenotypic, and genetic characteristics of DLBCL, but also in face of several 
breakthroughs in its treatment, the prognosis of this type of NHL has witnessed 
only modest improvements. The search for new biomarkers and efficient therapeu-
tic agents in the context of future individualized treatment will be crucial in our 
quest for improved results.
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ABC DLBCL activated B-cell DLBCL
B2M beta-2 microglobulin
Bcl-2 B-cell receptor 2
Bcl-6 B-cell receptor 6
CIITA class II MHC transactivator
c-Myc avian myelocytomatosis virus oncogene cellular homolog
CNS central nervous system
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FOXP1 forkhead box protein P1
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GCET1 germinal center B cell-expressed transcript 1
IRF4 interferon regulatory factor 4
MUM1 multiple myeloma 1 protein
NFkB nuclear factor kappa-light-chain-enhancer of activated B cells
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PDL 1 programmed death-ligand 1
PET-CT positron emission tomography-computed tomography
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R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, 
prednisone
R-CHOEP rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, 
and prednisone
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